Caris Life Sciences (CAI) Net Cash Flow (2024 - 2026)

Caris Life Sciences' Net Cash Flow history runs 3 years deep, the most recent figure standing at $23.4 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 171.34% year-over-year to $23.4 million; the TTM figure through Mar 2026 stood at $788.0 million (up 643.83% YoY), while the FY2025 annual figure was $731.9 million, up 9020.05% from the prior year.
• Net Cash Flow for Q1 2026 stood at $23.4 million, down from $43.1 million in the prior quarter.
• The five-year high for Net Cash Flow was $687.3 million in Q2 2025, with the low at -$71.2 million in Q3 2024.
• The 3-year median for Net Cash Flow is $23.4 million (2026), against an average of $91.9 million.
• Peak annual rise in Net Cash Flow reached 205.13% in 2025, while the deepest fall reached 148.1% in 2025.
• Caris Life Sciences' Net Cash Flow stood at -$41.0 million in 2024, then soared by 205.13% to $43.1 million in 2025, then tumbled by 45.79% to $23.4 million in 2026.
• Business Quant data shows CAI's Net Cash Flow at $23.4 million in Q1 2026, $43.1 million in Q4 2025, and $34.2 million in Q3 2025.